Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia
<ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ganiyu Olatubosun Arinola [verfasserIn] O B Idonije [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2009 |
|---|
| Schlagwörter: |
Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. |
|---|
| Übergeordnetes Werk: |
In: Journal of Research in Medical Sciences - Wolters Kluwer Medknow Publications, 2005, 14(2009), 1, Seite 37-42 |
|---|---|
| Übergeordnetes Werk: |
volume:14 ; year:2009 ; number:1 ; pages:37-42 |
| Links: |
|---|
| Katalog-ID: |
DOAJ024210730 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ024210730 | ||
| 003 | DE-627 | ||
| 005 | 20230307073059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2009 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ024210730 | ||
| 035 | |a (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Ganiyu Olatubosun Arinola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> | ||
| 650 | 4 | |a Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a O B Idonije |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Research in Medical Sciences |d Wolters Kluwer Medknow Publications, 2005 |g 14(2009), 1, Seite 37-42 |w (DE-627)608492930 |w (DE-600)2513075-4 |x 17357136 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2009 |g number:1 |g pages:37-42 |
| 856 | 4 | 0 | |u https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 |z kostenfrei |
| 856 | 4 | 0 | |u http://journals.mui.ac.ir/jrms/article/view/2469 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1735-1995 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1735-7136 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2009 |e 1 |h 37-42 | ||
| author_variant |
g o a goa o b i obi |
|---|---|
| matchkey_str |
article:17357136:2009----::ttsflsaircxdadoezmtcnixdnseoenatrniscoitetetn |
| hierarchy_sort_str |
2009 |
| publishDate |
2009 |
| allfields |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 DE-627 ger DE-627 rakwb eng Ganiyu Olatubosun Arinola verfasserin aut Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R O B Idonije verfasserin aut In Journal of Research in Medical Sciences Wolters Kluwer Medknow Publications, 2005 14(2009), 1, Seite 37-42 (DE-627)608492930 (DE-600)2513075-4 17357136 nnns volume:14 year:2009 number:1 pages:37-42 https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 kostenfrei http://journals.mui.ac.ir/jrms/article/view/2469 kostenfrei https://doaj.org/toc/1735-1995 Journal toc kostenfrei https://doaj.org/toc/1735-7136 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2009 1 37-42 |
| spelling |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 DE-627 ger DE-627 rakwb eng Ganiyu Olatubosun Arinola verfasserin aut Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R O B Idonije verfasserin aut In Journal of Research in Medical Sciences Wolters Kluwer Medknow Publications, 2005 14(2009), 1, Seite 37-42 (DE-627)608492930 (DE-600)2513075-4 17357136 nnns volume:14 year:2009 number:1 pages:37-42 https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 kostenfrei http://journals.mui.ac.ir/jrms/article/view/2469 kostenfrei https://doaj.org/toc/1735-1995 Journal toc kostenfrei https://doaj.org/toc/1735-7136 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2009 1 37-42 |
| allfields_unstemmed |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 DE-627 ger DE-627 rakwb eng Ganiyu Olatubosun Arinola verfasserin aut Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R O B Idonije verfasserin aut In Journal of Research in Medical Sciences Wolters Kluwer Medknow Publications, 2005 14(2009), 1, Seite 37-42 (DE-627)608492930 (DE-600)2513075-4 17357136 nnns volume:14 year:2009 number:1 pages:37-42 https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 kostenfrei http://journals.mui.ac.ir/jrms/article/view/2469 kostenfrei https://doaj.org/toc/1735-1995 Journal toc kostenfrei https://doaj.org/toc/1735-7136 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2009 1 37-42 |
| allfieldsGer |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 DE-627 ger DE-627 rakwb eng Ganiyu Olatubosun Arinola verfasserin aut Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R O B Idonije verfasserin aut In Journal of Research in Medical Sciences Wolters Kluwer Medknow Publications, 2005 14(2009), 1, Seite 37-42 (DE-627)608492930 (DE-600)2513075-4 17357136 nnns volume:14 year:2009 number:1 pages:37-42 https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 kostenfrei http://journals.mui.ac.ir/jrms/article/view/2469 kostenfrei https://doaj.org/toc/1735-1995 Journal toc kostenfrei https://doaj.org/toc/1735-7136 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2009 1 37-42 |
| allfieldsSound |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 DE-627 ger DE-627 rakwb eng Ganiyu Olatubosun Arinola verfasserin aut Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia 2009 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R O B Idonije verfasserin aut In Journal of Research in Medical Sciences Wolters Kluwer Medknow Publications, 2005 14(2009), 1, Seite 37-42 (DE-627)608492930 (DE-600)2513075-4 17357136 nnns volume:14 year:2009 number:1 pages:37-42 https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 kostenfrei http://journals.mui.ac.ir/jrms/article/view/2469 kostenfrei https://doaj.org/toc/1735-1995 Journal toc kostenfrei https://doaj.org/toc/1735-7136 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2009 1 37-42 |
| language |
English |
| source |
In Journal of Research in Medical Sciences 14(2009), 1, Seite 37-42 volume:14 year:2009 number:1 pages:37-42 |
| sourceStr |
In Journal of Research in Medical Sciences 14(2009), 1, Seite 37-42 volume:14 year:2009 number:1 pages:37-42 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Journal of Research in Medical Sciences |
| authorswithroles_txt_mv |
Ganiyu Olatubosun Arinola @@aut@@ O B Idonije @@aut@@ |
| publishDateDaySort_date |
2009-01-01T00:00:00Z |
| hierarchy_top_id |
608492930 |
| id |
DOAJ024210730 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024210730</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073059.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024210730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ganiyu Olatubosun Arinola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">&lt;ul&gt; &lt;li&gt;&lt;strong&gt;BACKGROUND&lt;/strong&gt;: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;METHODS&lt;/strong&gt;: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;RESULTS&lt;/strong&gt;: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated&lt;/li&gt; &lt;li&gt;schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;CONCLUSIONS&lt;/strong&gt;: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;KEYWORDS&lt;/strong&gt;: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.&lt;/li&gt; &lt;/ul&gt;</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O B Idonije</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Research in Medical Sciences</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2005</subfield><subfield code="g">14(2009), 1, Seite 37-42</subfield><subfield code="w">(DE-627)608492930</subfield><subfield code="w">(DE-600)2513075-4</subfield><subfield code="x">17357136</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://journals.mui.ac.ir/jrms/article/view/2469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1735-1995</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1735-7136</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2009</subfield><subfield code="e">1</subfield><subfield code="h">37-42</subfield></datafield></record></collection>
|
| author |
Ganiyu Olatubosun Arinola |
| spellingShingle |
Ganiyu Olatubosun Arinola misc Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. misc Medicine misc R Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| authorStr |
Ganiyu Olatubosun Arinola |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)608492930 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
17357136 |
| topic_title |
Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress |
| topic |
misc Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. misc Medicine misc R |
| topic_unstemmed |
misc Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. misc Medicine misc R |
| topic_browse |
misc Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress. misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Research in Medical Sciences |
| hierarchy_parent_id |
608492930 |
| hierarchy_top_title |
Journal of Research in Medical Sciences |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)608492930 (DE-600)2513075-4 |
| title |
Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| ctrlnum |
(DE-627)DOAJ024210730 (DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0 |
| title_full |
Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| author_sort |
Ganiyu Olatubosun Arinola |
| journal |
Journal of Research in Medical Sciences |
| journalStr |
Journal of Research in Medical Sciences |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2009 |
| contenttype_str_mv |
txt |
| container_start_page |
37 |
| author_browse |
Ganiyu Olatubosun Arinola O B Idonije |
| container_volume |
14 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ganiyu Olatubosun Arinola |
| author2-role |
verfasserin |
| title_sort |
status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in nigerian patients with schizophrenia |
| title_auth |
Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| abstract |
<ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> |
| abstractGer |
<ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> |
| abstract_unstemmed |
<ul> <li><strong>BACKGROUND</strong>: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.</li> <li><strong>METHODS</strong>: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.</li> <li><strong>RESULTS</strong>: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated</li> <li>schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.</li> <li><strong>CONCLUSIONS</strong>: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.</li> <li><strong>KEYWORDS</strong>: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</li> </ul> |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia |
| url |
https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0 http://journals.mui.ac.ir/jrms/article/view/2469 https://doaj.org/toc/1735-1995 https://doaj.org/toc/1735-7136 |
| remote_bool |
true |
| author2 |
O B Idonije |
| author2Str |
O B Idonije |
| ppnlink |
608492930 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| up_date |
2024-07-03T21:47:48.191Z |
| _version_ |
1803596089987694593 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ024210730</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307073059.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2009 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ024210730</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0ae7326603ed4f708475de06e724cdf0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ganiyu Olatubosun Arinola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Status of plasma nitric oxide and non-enzymatic antioxidants before and after antipsychotic treatment in Nigerian patients with schizophrenia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2009</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">&lt;ul&gt; &lt;li&gt;&lt;strong&gt;BACKGROUND&lt;/strong&gt;: Recently, it is proposed that oxidant-antioxidant imbalance may have a role in the pathophysiology of schizophrenia. The present study was performed to assess differences in plasma levels of nitric oxide (as oxidant), caeruloplasmin (secondary antioxidant), and antioxidant trace metals (Zn, Se, Mn, Cu and Fe) in patients with schizophrenia compared with healthy controls. Our secondary aim was to further evaluate the impact of psychopharmacologic treatment on these parameters.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;METHODS&lt;/strong&gt;: Plasma levels of nitric oxides (NO), caeruloplasmin, zinc (Zn), selenium (Se), manganese (Mn), copper (Cu) and iron (Fe) in patients with schizophrenia before (n = 15) and after antipsychotic drug treatment (n = 20) were compared with those of healthy controls (n = 20). Convenient sampling method was used for the selection of subjects. NO was estimated by the use of Griess method, caeruloplasmin was estimated by the use of immunodiffusion method and antioxidant trace metals was estimated by the use of atomic absorption spectrophotometer.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;RESULTS&lt;/strong&gt;: The levels of Cu and caeruloplasmin were not significantly different while Fe and Se were significantly reduced in both groups of schizophrenic patients compared with the controls. Zn was significantly elevated in medicated&lt;/li&gt; &lt;li&gt;schizophrenics compared with drug-free patients or controls. NO was significantly elevated in drug free patients with schizophrenia compared with controls or treated patients.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;CONCLUSIONS&lt;/strong&gt;: Our findings suggest the application of management strategies that will reduce NO but will increase antioxidant trace metals in patients with schizophrenia.&lt;/li&gt; &lt;li&gt;&lt;strong&gt;KEYWORDS&lt;/strong&gt;: Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.&lt;/li&gt; &lt;/ul&gt;</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Schizophrenia, antioxidant defense system, antioxidant status, oxidative Stress.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O B Idonije</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Research in Medical Sciences</subfield><subfield code="d">Wolters Kluwer Medknow Publications, 2005</subfield><subfield code="g">14(2009), 1, Seite 37-42</subfield><subfield code="w">(DE-627)608492930</subfield><subfield code="w">(DE-600)2513075-4</subfield><subfield code="x">17357136</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2009</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:37-42</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0ae7326603ed4f708475de06e724cdf0</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://journals.mui.ac.ir/jrms/article/view/2469</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1735-1995</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1735-7136</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2009</subfield><subfield code="e">1</subfield><subfield code="h">37-42</subfield></datafield></record></collection>
|
| score |
7.4005175 |